Zhang Zhengguang, Siegert Joachim, Maywald Ulf, Kirch Wihelm
Institut für Klinische Pharmakologie, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden.
Med Klin (Munich). 2007 Jul 15;102(7):540-9. doi: 10.1007/s00063-007-1068-6.
Cost-benefit analyses are helpful in setting priorities for funding health-care programs. The authors studied the cost/benefit of treatment with radium-224 compared to the treatment without radium-224 in patients with ankylosing spondylitis (AS).
The data of a 2-year retrospective observational study were used to estimate cost/benefit of [224Ra] therapy. Twelve patients treated with [224Ra], complete recruit in AOK Saxony, matched (age, gender, employment status) with twelve patients receiving conservative treatment without [224Ra], were compared for lost productivity and direct medical costs, such as doctor visits, medication and hospitalization, 1 year before and after treatment.
1 year after the first i.v. injection of [224Ra], all cost factors in the case group were reduced compared to 1 year before treatment with [224Ra] (hospitalization 29.4%, doctor visits 23.5%, medication 9.4%, and lost productivity even 82.3%). The total costs decreased by an average of 3,870 Euros. Because of the small sample the differences showed a trend but were not significant.
The use of [224Ra] in patients with AS seems to reduce lost productivity and direct medical costs, but additional studies based on more patients and long-term data are needed.
成本效益分析有助于确定医疗保健项目的资金优先顺序。作者研究了与未使用镭 - 224治疗相比，使用镭 - 224治疗强直性脊柱炎（AS）患者的成本效益。
一项为期2年的回顾性观察研究数据用于估算[224Ra]治疗的成本效益。将在AOK萨克森州完全招募的12例接受[224Ra]治疗的患者，与12例接受无[224Ra]保守治疗的患者（年龄、性别、就业状况匹配），在治疗前后1年比较生产力损失和直接医疗成本，如就诊、用药和住院费用。
首次静脉注射[224Ra]后1年，与使用[224Ra]治疗前1年相比，病例组的所有成本因素均降低（住院费用降低29.4%，就诊费用降低23.5%，用药费用降低9.4%，生产力损失甚至降低82.3%）。总成本平均降低了3870欧元。由于样本量小，差异呈趋势但不显著。
在AS患者中使用[224Ra]似乎可降低生产力损失和直接医疗成本，但需要基于更多患者和长期数据的进一步研究。
